RxSight faces securities fraud lawsuit from Bleichmar Fonti & Auld LLP

A legal action has been initiated against RxSight, Inc. and its top management for possible breaches of federal securities regulations. The lawsuit is based on alleged infringements of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors who acquired RxSight securities. Interested investors have until September 22, 2025, to request to be selected as the lead plaintiff in the lawsuit.

Individuals holding investments in RxSight, Inc. (NASDAQ: RXST) were informed about a class action lawsuit regarding securities fraud filed against the corporation and its executives. The litigation is currently under review in the U.S. District Court for the Central District of California and asserts violations of federal securities laws. The deadline for investors to request being appointed as the lead plaintiff is September 22, 2025.

The lawsuit brought forward by the Law Offices of Frank R. Cruz alleges that from November 7, 2024, to July 8, 2025, RxSight did not disclose various crucial issues to investors. These encompassed “adoption challenges” and structural problems that resulted in a decrease in sales and utilization of the company’s Light Adjustable Lens (LAL) products. Furthermore, the complaint contends that RxSight exaggerated the demand for its products and issued deceptive statements regarding its business outlook.

Furthermore, as per the lawsuit, the omissions and misrepresentations caused investors to suffer losses. Following the revision of RxSight’s 2025 full-year revenue forecast on April 3, 2025, and July 8, 2025, the company’s stock price experienced significant drops. The stock price witnessed a decline of about 38% on both occasions.

Investors who acquired RxSight securities during the specified period are advised to relay their details to the law firms handling the case. The Law Offices of Frank R. Cruz, Bleichmar Fonti & Auld LLP, and the Rosen Law Firm have all communicated their participation in the lawsuit and have shared contact information for investors seeking further information.

In conclusion, investors are urged to take action promptly if they believe they are eligible to join the lawsuit as a lead plaintiff before the September 22, 2025 deadline.